Teleflex Incorporated (NYSE:TFX) – Equities researchers at KeyCorp issued their Q1 2018 earnings estimates for shares of Teleflex in a research report issued on Thursday. KeyCorp analyst M. Mishan expects that the medical technology company will earn $1.95 per share for the quarter. KeyCorp also issued estimates for Teleflex’s Q2 2018 earnings at $2.43 EPS, Q3 2018 earnings at $2.43 EPS, Q4 2018 earnings at $2.84 EPS and FY2018 earnings at $9.65 EPS.
TFX has been the topic of a number of other reports. Morgan Stanley increased their target price on Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Jefferies Group increased their target price on Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Leerink Swann reissued a “buy” rating and issued a $321.00 target price (up from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. Deutsche Bank cut Teleflex from a “buy” rating to a “hold” rating and set a $251.00 target price on the stock. in a research note on Tuesday, November 14th. Finally, Stephens reissued a “buy” rating and issued a $300.00 target price on shares of Teleflex in a research note on Thursday, January 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating to the company. Teleflex currently has an average rating of “Hold” and an average target price of $281.56.
Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 22nd. The medical technology company reported $2.44 EPS for the quarter, topping analysts’ consensus estimates of $2.40 by $0.04. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The firm had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $601.17 million. During the same period in the prior year, the firm posted $2.13 earnings per share. The company’s quarterly revenue was up 15.8% on a year-over-year basis.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, March 1st. Teleflex’s payout ratio is currently 41.59%.
In other news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $265.32, for a total transaction of $53,064.00. Following the transaction, the director now directly owns 8,080 shares of the company’s stock, valued at $2,143,785.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total value of $658,450.00. Following the transaction, the director now directly owns 10,583 shares in the company, valued at $2,787,350.54. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,100 shares of company stock worth $2,671,994. Corporate insiders own 2.39% of the company’s stock.
A number of hedge funds have recently bought and sold shares of TFX. Cornerstone Capital Management Holdings LLC. bought a new position in Teleflex in the second quarter valued at about $175,000. Aperio Group LLC lifted its holdings in Teleflex by 4.4% in the third quarter. Aperio Group LLC now owns 13,599 shares of the medical technology company’s stock valued at $3,290,000 after acquiring an additional 571 shares during the period. Pictet Asset Management Ltd. lifted its holdings in Teleflex by 5.3% in the third quarter. Pictet Asset Management Ltd. now owns 15,170 shares of the medical technology company’s stock valued at $3,671,000 after acquiring an additional 770 shares during the period. Crossmark Global Holdings Inc. bought a new position in Teleflex in the third quarter valued at about $1,327,000. Finally, Victory Capital Management Inc. lifted its holdings in Teleflex by 15.9% in the third quarter. Victory Capital Management Inc. now owns 8,488 shares of the medical technology company’s stock valued at $2,054,000 after acquiring an additional 1,163 shares during the period. 88.98% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.tickerreport.com/banking-finance/3222248/keycorp-comments-on-teleflex-incorporateds-q1-2018-earnings-tfx.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.